Full Press Release Details
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024.
GLUE
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
Key Takeaway: Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
Price reaction · baseline $5.525 (2024-01-05 close) · 1 other GLUE headline(s) in the window, move may be shared
day 0 close
+14.4%
day 1 · peak
+39.5%
day 3
+11.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+67%
120-day peak, hindsight
Typical move
13.3%
average across 9 past catalysts
Cash runway
~41 mo
Minimal dilution risk
Lead asset
MRT-2359
Phase 2 · Castration-Resistant Prostate Cancer (CRPC)